• In July 2026, Edwards Lifesciences reported second-quarter 2026 results showing sales of US$1.74 billion and net income of US$241.9 million, while issuing third-quarter sales guidance of US$1.63 billion to US$1.71 billion.
• The company also raised its full-year 2026 sales growth guidance and increased expectations for its TAVR and TMTT product lines, underlining management’s confidence in demand for its structural heart therapies.
• Next, we’ll examine how Edwards’ upgraded full-year 2026 sales outlook could influence the existing investment narrative built around TAVR expansion.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you have to believe in long term adoption of its transcatheter heart therapies, especially TAVR and TMTT, supported by strong clinical data and innovation. The raised 2026 sales guidance reinforces that demand story in the near term, but does not remove key risks around tariffs, competitive pressure in international TAVR markets, and the earnings drag from recent acquisitions, which remain important short term watchpoints.

The most relevant update here is Edwards’ decision to lift its full year 2026 sales growth guidance to 10% to 11%, with higher TAVR and TMTT expectations. This directly ties into the early TAVR indication and broader structural heart pipeline as central catalysts, while putting more focus on whether the company can manage higher R&D and integration costs without further compressing margins.

However, investors should also be aware that rising tariff impacts and acquisition related dilution could still weigh on earnings momentum and valuation multiples...

Edwards Lifesciences' narrative projects $8.5 billion revenue and $2.2 billion earnings by 2029. This requires 9.3% yearly revenue growth and about a $1.2 billion earnings increase from $979.9 million today.

Uncover how Edwards Lifesciences' forecasts yield a $100.96 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Edwards Lifesciences between US$91.29 and US$100.96 per share, highlighting a tight cluster of views. Against that, the upgraded 2026 sales outlook and heavier focus on TAVR and TMTT growth keeps the spotlight on whether margin pressures from tariffs and acquisitions will limit how much of this demand reaches the bottom line.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 13% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.